- Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
- Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
- Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
- Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
More ▼
Key statistics
On Thursday, Fulcrum Therapeutics Inc (FULC:NMQ) closed at 7.06, 191.74% above the 52 week low of 2.42 set on Apr 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.15 |
---|---|
High | 7.21 |
Low | 6.90 |
Bid | 2.83 |
Offer | 11.29 |
Previous close | 7.06 |
Average volume | 495.17k |
---|---|
Shares outstanding | 61.94m |
Free float | 61.08m |
P/E (TTM) | -- |
Market cap | 437.26m USD |
EPS (TTM) | -1.59 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼